Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Uniqure N.V. (QURE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,020,516
  • Shares Outstanding, K 37,626
  • Annual Sales, $ 11,280 K
  • Annual Income, $ -83,300 K
  • 60-Month Beta 1.08
  • Price/Sales 182.13
  • Price/Cash Flow N/A
  • Price/Book 11.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.66
  • Number of Estimates 6
  • High Estimate -0.59
  • Low Estimate -0.71
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -11.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.73 +1.84%
on 04/18/19
69.60 -22.84%
on 03/21/19
-12.08 (-18.36%)
since 03/18/19
3-Month
30.24 +77.60%
on 01/23/19
69.60 -22.84%
on 03/21/19
+22.34 (+71.24%)
since 01/18/19
52-Week
21.98 +144.31%
on 11/14/18
69.60 -22.84%
on 03/21/19
+21.87 (+68.71%)
since 04/18/18

Most Recent Stories

More News
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 53.70 (-1.68%)
Potential Blockbuster Gene Therapy Programs to Watch in 2019

Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable.

SGMO : 11.70 (unch)
QURE : 53.70 (-1.68%)
BLUE : 137.06 (-1.67%)
LPTX : 1.62 (-1.22%)
GNPX : 1.76 (-2.49%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
SRPT : 116.64 (-1.76%)
OPHT : 1.39 (-0.71%)
NITE : 25.51 (+0.04%)
RGNX : 54.65 (-0.13%)
BOLD : 38.90 (+0.96%)
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has...

QURE : 53.70 (-1.68%)
uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 29, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 53.70 (-1.68%)
uniQure to Participate in Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 53.70 (-1.68%)
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress

~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~

QURE : 53.70 (-1.68%)
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
RGNX : 54.65 (-0.13%)
EDIT : 25.80 (+0.31%)
uniQure Presents New Preclinical Data on AMT-130 at the CHDI's 14th Annual Huntington's Disease Therapeutics Conference

~ AMT-130 Shows Restoration of Brain Cell Function and Reversal of Neuropathology in Huntington's Disease Mouse Model ~

QURE : 53.70 (-1.68%)
Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
PBE : 51.76 (-0.46%)
SBIO : 33.66 (+0.18%)
CRSP : 36.26 (-0.47%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
BLUE : 137.06 (-1.67%)
NVS : 76.41 (-1.15%)
BOLD : 38.90 (+0.96%)
RHHBY : 32.6900 (-0.09%)
XBI : 84.63 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade QURE with:

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

2nd Resistance Point 56.61
1st Resistance Point 55.16
Last Price 53.70
1st Support Level 52.49
2nd Support Level 51.27

See More

52-Week High 69.60
Last Price 53.70
Fibonacci 61.8% 51.41
Fibonacci 50% 45.79
Fibonacci 38.2% 40.17
52-Week Low 21.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar